Table 1 Summary of clinical studies of PD-1/PD-L1 in human specimens
Reference setting | PD-1/PD-L1 | IPF patients/normal or other disease numbers | Sample | Method | Expression change |
|---|---|---|---|---|---|
Jovanovic [66] | mPD-L1 sPD-L1 | 12/– 23/– | Lung Plasma | IHC LISA | Upregulation Elevation |
Celada [67] | PD-1 PD-L1 | 10/5 25/24 10/5 | Lung Peripheral blood | IHC FCM IHC | Upregulation Upregulation Upregulation |
Guo [23] | PD-L1 | 3/3 | Lung | IF | Upregulation |
Cui [76] | PD-L1 | 11/3 | Lung | Mass cytometry | Upregulation |
Bonham [68] | PD-1 | 41/13 | Peripheral blood | FCM | No change |
Wang [69] | PD-1 PD-L1 | 23//25 23//25 | Peripheral blood Peripheral blood | FCM | Upregulation Upregulation |
Milenkovic [70] | sPD-L1 | 30/30 | Plasma | ELISA | Elevation |
Guyard [71] | PD-L1 | 18/13 (all complicated lung cancer) | Lung | IHC | Upregulation |
Kronborg-White [72] | mPD-L1 | 43/55 | Lung | IHC | Upregulation |
Asai [73] | PD-1 | 18/21 | Peripheral blood | FCM | Upregulation |
Li [74] | PD-L1 | 16/8 8/10 12/12 | Lung BALF Serum | IHC ELISA ELISA | Upregulation Elevation Elevation |
Ahmadvand [75] | CD274 PD-1 | 9/12 | Lung | FCM/RT-PCR | Upregulation Upregulation |